Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

PLRZ

Polyrizon (PLRZ)

Polyrizon Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PLRZ
DateTimeSourceHeadlineSymbolCompany
19/03/202522:35GlobeNewswire Inc.Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug CombinationNASDAQ:PLRZPolyrizon Ltd
19/03/202515:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PLRZPolyrizon Ltd
14/03/202523:38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PLRZPolyrizon Ltd
14/03/202523:35GlobeNewswire Inc.Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based TreatmentsNASDAQ:PLRZPolyrizon Ltd
14/03/202507:42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PLRZPolyrizon Ltd
13/03/202522:51GlobeNewswire Inc.Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge PlatformNASDAQ:PLRZPolyrizon Ltd
12/03/202507:27GlobeNewswire Inc.Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024NASDAQ:PLRZPolyrizon Ltd
12/03/202507:23Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PLRZPolyrizon Ltd
12/03/202507:05Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:PLRZPolyrizon Ltd
11/03/202508:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PLRZPolyrizon Ltd
10/03/202522:47GlobeNewswire Inc.Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T PlatformNASDAQ:PLRZPolyrizon Ltd
06/03/202508:00Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:PLRZPolyrizon Ltd
30/01/202522:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PLRZPolyrizon Ltd
30/01/202521:55GlobeNewswire Inc.Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery PlatformNASDAQ:PLRZPolyrizon Ltd
24/01/202500:59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PLRZPolyrizon Ltd
23/01/202522:40GlobeNewswire Inc.Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical TrialNASDAQ:PLRZPolyrizon Ltd
23/01/202508:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PLRZPolyrizon Ltd
22/01/202508:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PLRZPolyrizon Ltd
16/01/202516:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PLRZPolyrizon Ltd
11/01/202508:16Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:PLRZPolyrizon Ltd
31/12/202408:52Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:PLRZPolyrizon Ltd
30/12/202422:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PLRZPolyrizon Ltd
30/12/202422:25GlobeNewswire Inc.Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal TechnologiesNASDAQ:PLRZPolyrizon Ltd
20/12/202400:21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PLRZPolyrizon Ltd
19/12/202423:22GlobeNewswire Inc.Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical AffairsNASDAQ:PLRZPolyrizon Ltd
18/12/202422:25GlobeNewswire Inc.Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy BlockerNASDAQ:PLRZPolyrizon Ltd
14/12/202408:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PLRZPolyrizon Ltd
13/12/202422:25GlobeNewswire Inc.Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality AssuranceNASDAQ:PLRZPolyrizon Ltd
03/12/202408:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PLRZPolyrizon Ltd
03/12/202400:02GlobeNewswire Inc.Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical TrialNASDAQ:PLRZPolyrizon Ltd
 Showing the most relevant articles for your search:NASDAQ:PLRZ